Improvements with GLP-1 RAs in psoriasis and other chronic skin diseases point to their increased use in dermatology and a ...

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has gained attention in various research studies ...

In 2023, the Blue Shield of California announced that it was dropping CVS Caremark as its pharmacy benefit manager (PBM) and ...

Fact checked by Nick Blackmer Tirzepatide and semaglutide, the ingredients in popular weight loss drugs, can both cause side ...

Children who are living with severe obesity are more likely to experience a clinically relevant change in BMI when GLP-1 ...

Hidden fat stored deep within muscles can significantly raise your risk of heart disease, heart attacks, and heart failure, ...

A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and ...

Digital programs incorporating behavioral therapy led to solid reductions in body weight, and did so at lower drug doses.

GLP-1 RAs are associated with a significant decrease in apnea-hypopnea index among patients with moderate to severe OSA and without diabetes.

While GLP-1 receptor agonists and bariatric surgery offer significant metabolic benefits, experts caution that rapid weight ...

First-generation GLP-1 weight-loss drugs can help reduce the risk of obesity-related cancers, new research shows. Liraglutide ...

A study has found that glucagon-like peptide-1 receptor agonists (GLP-1RAs) offer anti-cancer benefits that extend beyond ...